Module 3 - Screening for Depression in Primary Care

Screening for Depression in Primary Care

Activity Details
  • Credit Type: CNE
  • Credit Amount: 0.50
  • Cost: Free
  • Release: May 3, 2021
  • Expires: May 2, 2024
  • Estimated Time to Complete:
    30 Minutes
  • Average User Rating:
    ( Ratings)

Faculty

Caroline Barnhart Caroline Barnhart, MSS, LCSW
Director of Behavioral Health
Penn Medicine
Lancaster General Health
Lancaster, Pennsylvania

James D.  Hawthorne III James D. Hawthorne III, MD
Medical Director, Adult Inpatient Unit
UK Good Samaritan Hopsital
Assistant Professor, Psychiatry
University of Kentucky College of Medicine
Lexington, Kentucky

Needs Statement

Did you know that half of all patients with major depressive disorder (MDD) are diagnosed and treated by their primary care provider?

Also, as many as half of patients with MDD in primary care remain undiagnosed, so they are not receiving the treatment that they need. Less than one third of people with depression actually receive appropriate treatment

This activity explains why screening for depression is so important and what tools are available to help with screening.

Target Audience

This activity is intended for registered nurses involved with the management or treatment of patients with major depressive disorder (MDD).

Objectives

Upon completion of this activity, participants will be able to:

  • Explain the improtance of screening for depression in the primary care setting
  • Review screening for depression with the Patient Health Questinnaire-9 (PHQ-9)

Accreditation

In support of improving patient care, this activity has been planned and implemented by UK HealthCare CECentral and DKBmed. University of Kentucky HealthCare CECentral is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

CNE
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.50 nursing contact hours.

Faculty Disclosure

No speakers, authors, planners or content reviewers have any relevant financial relationships to disclose.

The material presented in this course represents information obtained from the scientific literature as well as the clinical experiences of the speakers. In some cases, the presentations might include discussion of investigational agents and/or off-label indications for various agents used in clinical practice. Speakers will inform the audience when they are discussing investigational and/or off-label uses.

Content review confirmed that the content was developed in a fair, balanced manner free from commercial bias. Disclosure of a relationship is not intended to suggest or condone commercial bias in any presentation, but it is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Acknowledgment

The program is jointly provided by the University of Kentucky College of Medicine and DKBmed in collaboration with Postgraduate Institute for Medicine.

This activity is supported by an independent educational grant from Takeda Pharmaceuticals North America, Inc. and Otsuka America Pharmaceutical, Inc.